Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients at the Digital International Liver Congress™ 2020
27 août 2020 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on discovering and developing differentiated therapies to treat liver and...
Metacrine Announces MET409 Receives FDA Fast Track Designation for the Treatment of NASH
25 août 2020 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver...
Metacrine Appoints Pharmaceutical Business and R&D Executive, Preston Klassen, M.D., MHS, as President and Chief Executive Officer
09 juin 2020 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class drugs to treat patients with liver and...
Metacrine to Present at Jefferies 2019 London Healthcare Conference
18 nov. 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures
18 sept. 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine Doses First Patient in 12-Week NASH Proof-of-Concept Trial with a Sustained FXR Agonist
09 juil. 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, July 09, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019
02 juil. 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients
29 mai 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present at Jefferies 2019 Global Healthcare Conference
21 mai 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019
13 mai 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...